UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert Jan Creemers, Birgit A.L.M. Deiman, Jesse J. Swen, Saskia Houterman, Stijn L.W. Koolen, Sander Bins, Anna M.J. Thijs, Marjan M.J. Laven, Anke M. Hövels, Saskia A.C. Luelmo, Danny Houtsma, Katerina Shulman, Howard L. McLeod, Ron H.N. van Schaik, Henk Jan Guchelaar, Ron H.J. Mathijssen, Hans GelderblomMaarten J. Deenen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)

Fingerprint

Dive into the research topics of 'UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science